Cerulean Pharma hopes to secure money in a new funding round to further develop CRLX101, a nanoparticle-based drug designed to treat solid tumors such as lung cancer, CEO Oliver Fetzer said. Fetzer added that the Cambridge, Mass.-based company has started recruiting patients in a Phase IIa trial after the drug performed well in a preliminary study.

Full Story:

Related Summaries